Times, they are a’changin’ at Australian medical cannabis company AusCann (ASX:AC8) – it’s been a busy past week for the company.
On Monday, AusCann announced its joint venture with Fundación Daya, DayaCann, has signed a non-binding Memorandum of Understand (MoU) with Khiron Life Sciences Corp.
While Canadian Venture Exchange listed (CVE: KHRN), Khiron’s operations are focused in Colombia where it has licenses for the cultivation, production, distribution and export of medical cannabis
Under the MoU, DayaCann, Fundación Daya and Khiron will be collaborating on the development of social, teaching, scientific, commercial and other activities to support the use of cannabinoid medicines in Chile in addition to those already being supplied by the latter two.
“The MoU will not only expand DayaCann’s presence in Chile, but also give DayaCann wider access to the Latin American market,” said AusCann Managing Director Elaine Darby.
While on the topic of education – and closer to home – yesterday AusCann said it had released online education courses as part of its Medical Outreach Program to support Australian health professionals in making decisions regarding cannabinoid-based therapeutics.
“Until it becomes part of the medical syllabus, there is a need to provide accessible, referenced, objective information about cannabinoid medicines that doctors and other health professionals can draw upon to inform their thinking,” said AusCann’s Chairman, Dr Mal Washer.
Dr. Washer was educated at the University of Western Australia, graduating in 1970 with degrees in medicine and surgery; then going on to establish a number of medical centres in Western Australia. Dr. Washer, who provided input for the online courses, also has a background in agricultural and horticultural activities.
The courses were developed with assistance of AusCann’s Chief Medical Advisor, Dr Danial Schecter, and experts in online teaching resources.
The courses can be accessed on AusCann’s website and are free to registered Australian health professionals, meaning an Australian Health Practitioner Regulation Agency (AHPRA) number is required.
In other developments, late last month Elaine Darby advised the Board she intends to step down as Managing Director. Ms. Darby will stay on until such time suitable arrangements have been made to for handover of responsibilities. On the same day, AusCann announced pharmaceutical executive, Dr Paul MacLeman, had joined the company’s Board as an Executive Director.
